Double success for University drug resistance research

Swansea University research into the threat posed by antifungal drug resistance has been highlighted in two prestigious international journals. Fungal disease now kills more people than malaria or TB and the Centre for Disease Control in the USA recognises emergence of multi-drug resistance in fungi as a high level threat.

Dr Josie Parker and Prof Steve Kelly, from Swansea University Medical School's Centre for Cytochrome P450 Diversity have been involved in the studies which investigated different aspects of resistance

The first publication in the American Microbiology Society journal mBio saw them working with fellow academics from the University of Lausanne led by Professor Dominque Sanglard to compare whole genomes to identify key mutations involved in resistance to the drugs available that include azoles, amphotericin B and echinocandins.

A second publication in Nature Communications involved an international collaboration led by Manchester University's Professor Paul Bowyer and Dr Mike Bromley.

It examined drug resistance in the filamentous fungal pathogen Aspergillus fumigatus. Breathing in the airborne spores of this fungus can cause the devastating disease invasive aspergillosis which causes more than 200,000 life-threatening infections every year.

Professor Kelly, who has been researching the field of antifungal resistance for more than 30 years, said: "We are very pleased to be involved in both these research projects and that they have been published in such well-regarded journals.

"Improving our understanding of antifungal drug resistance will help in the development of effective and potentially life-saving therapies for the future."

Abhilash Kannan, Sandra A. Asner, Emilie Trachsel, Steve Kelly, Josie Parker, Dominique Sanglard.
Comparative Genomics for the Elucidation of Multidrug Resistance in Candida lusitaniae.
mBio Dec 2019, 10 (6). doi: 10.1128/mBio.02512-19.

Takanori Furukawa, Norman van Rhijn, Marcin Fraczek, Fabio Gsaller, Emma Davies, Paul Carr, Sara Gago, Rachael Fortune-Grant, Sayema Rahman, Jane Mabey Gilsenan, Emma Houlder, Caitlin H Kowalski, Shriya Raj, Sanjoy Paul, Peter Cook, Josie E Parker, Steve Kelly, Robert A Cramer, Jean-Paul Latgé, Scott Moye-Rowley, Elaine Bignell, Paul Bowyer, Michael J Bromley.
The negative cofactor 2 complex is a key regulator of drug resistance in Aspergillus fumigatus.
Nat Commun 11, 427 (2020). doi: 10.1038/s41467-019-14191-1.

Most Popular Now

BioMotiv and Bristol-Myers Squibb announce the lau…

BioMotiv, a mission-driven drug development accelerator associated with The Harrington Project for discovery and development, that advances breakthrough discoveries from ...

CEPI and GSK announce collaboration to strengthen …

CEPI, the Coalition for Epidemic Preparedness Innovations, and GSK announced a new collaboration aimed at helping the global effort to develop a vaccine for the 2019-nCoV...

Sandoz completes acquisition of Aspen's Japanese o…

Sandoz today announced that it has successfully completed the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen ...

Sanofi brain-penetrant BTK inhibitor meets primary…

The Sanofi Phase 2b study evaluating its investigational BTK (Bruton's tyrosine kinase) inhibitor (SAR442168), an oral, brain-penetrant, selective small molecule, achieve...

Roche reports very strong results in 2019

In 2019, Group sales rose 9% to CHF 61.5 billion and core EPS grew 13%, ahead of sales. The core operating profit increased 11%, reflecting the strong underlying business...

Merck donates one billionth praziquantel tablet

Merck, a leading science and technology company, today announced that it has already donated 1 billion tablets of praziquantel, the standard medication for the treatment ...

Bayer and Nuvisan create new research unit in Berl…

Bayer AG today announced that it entered into a definitive agreement to transfer a large part of its Berlin-based small molecule research unit to Nuvisan, an internationa...

Novartis announces MET inhibitor capmatinib (INC28…

Novartis announced that the US Food and Drug Administration (FDA) accepted and granted Priority Review to capmatinib’s (INC280) New Drug Application (NDA). Capmatinib is ...

WHO, China leaders discuss next steps in battle ag…

The Director-General of the World Health Organization (WHO), Dr Tedros Adhanom Ghebreyesus, met President Xi Jinping of the People's Republic of China in Beijing. They sh...

FDA approves first drug for treatment of peanut al…

Today the U.S. Food and Drug Administration approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, tha...

Can bilingualism protect the brain even with early…

A study by York University psychology researchers provides new evidence that bilingualism can delay symptoms of dementia. Alzheimer's disease is the most common form of d...

Poliovirus therapy shows potential as cancer vacci…

A modified form of poliovirus, pioneered at Duke Cancer Institute as a therapy for glioblastoma brain tumors, appears in laboratory studies to also have applicability for...